National Institute for Health and Care Excellence

Many express concerns about the impact that AI has on trust, fairness and transparency. As an evidence-based guidance producer for more than 25 years, the moment is right for NICE to listen to the public’s views on AI. That is the purpose of NICE Listens – our deliberative public engagement programme, designed to explore the moral, social and ethical questions that sit behind complex decisions.

It will especially benefit people who need help to inject their insulin as it will mean fewer visits from carers or healthcare workers, and less disruption to everyday life. This could particularly benefit some frailer people, and those with sight loss, limited hand movement, learning disabilities or difficulty following the steps involved.

Every day, practitioners make decisions about patient care based on the evidence and guidance available to them, but that information can come from different evidence sources meaning that the care that follows is not always consistent. Modern Service Frameworks (MSFs) aim to change that, by bringing the best available evidence together in one place for each priority area, using the evidence base as a backdrop to support service implementation.

MCL is a rare and aggressive type of non-Hodgkin lymphoma. It is considered incurable with current treatments and often comes back. Many people are diagnosed when the disease is at an advanced stage and often are not well enough to have a stem cell transplant, which limits their options.

Artificial intelligence is no longer the preserve of science fiction. In a matter of years, it has become a part of our everyday lives, helping us to work, communicate and solve problems in new and unexpected ways. Healthcare is no exception. Artificial intelligence is moving rapidly from promise to practice. Around the world, AI is already helping clinicians interpret medical images, supporting earlier diagnosis, identifying people at risk of illness and reducing administrative burdens.

Aficamten, also known as Myqorzo, is a once-daily pill for people with obstructive hypertrophic cardiomyopathy (HCM) - a condition where the heart muscle becomes thickened and stiff, making it harder for the heart to pump blood around the body. It can cause exhaustion, dizziness, breathlessness, chest pain and a racing or irregular heartbeat. Around 1 in 500 people in the UK has HCM, and in roughly half of cases it is inherited.

In this episode we explore the draft NICE guideline for PMOS (formerly known as PCOS), out for public consultation until 11 August 2026. We're joined by guideline committee members Aled Rees, professor of endocrinology at Cardiff University, and Sharon Manship, a lay member with lived experience of PMOS.

With only 1 in 5 donated lungs currently considered suitable for use, the introduction of the XVIVO Perfusion System for a 4-year period while evidence is generated, could benefit hundreds of NHS patients. An independent NICE committee has recommended the technology can be used so that evidence can be generated to address any benefits and costs that have not been fully captured in the current evidence base and economic evaluation.

I’ve had heart health issues for most of my life; I was born with a hole in my heart which did resolve itself but left me with hypertrophic cardiomyopathy, a disease where the heart muscle becomes thickened. My condition got steadily worse and in 2019 I was diagnosed with severe heart failure. I’ve got a new lease of life, and I’ve got to meet my grandson, which is the most precious gift of all. I signed up to be part of a clinical trial called Triage HF.

Heart failure with preserved or mildly reduced ejection fraction happens when the left side of the heart doesn't fill properly with blood during the diastolic (filling) phase. This means the heart is unable to pump enough blood to meet the body’s needs. Heart failure with preserved or mildly reduced ejection fraction means the reduction in blood pumped is smaller than for heart failure with reduced ejection fraction.